// App-Quantinova.ai

: Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy

Researchers

Presenter

  • Robert Frank Cornell

Principal Investigators

  • Samuel Z. Goldhaber

  • Brian G Engelhardt

  • Javid Moslehi

  • Madan Jagasia

  • Daryl Patton

  • Shelton Lacy Harrell

  • Robert L Hall

  • Houston Wyatt

  • Gregory Piazza

Medical Centers

  • Division of Epidemiology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN

  • Cardiovascular Division, Brigham and Womens Hospital, Harvard Medical School, Boston, MA

  • Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN

  • The Vanderbilt Inst for Clinical and Translational Res, Nashville, TN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • apixaban

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • IV

Study Id's

  • NCT02958969

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved